15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $216M | -$221M | 0.0% | -70.0% | -$110M | — | $85M |
| 2024 | $199M | -$19M | 0.0% | -20.5% | -$16M | — | $102M |
| 2023 | $193M | $3M | 0.0% | -7.2% | $12M | — | $136M |
| 2022 | $254M | $6M | 0.0% | 2.5% | $31M | — | $135M |
| 2021 | $269M | $33M | 0.0% | 15.7% | $64M | — | $52M |
| 2020 | $248M | $23M | 0.0% | 11.0% | $50M | — | $61M |
| 2019 | $227M | $116M | 0.0% | 10.0% | $45M | — | $45M |
| 2018 | $193M | $25M | 0.0% | 11.3% | $30M | — | $61M |
| 2017 | $165M | -$16M | 0.0% | -10.2% | -$4M | — | $34M |
| 2016 | $146M | -$18M | 0.0% | -12.7% | — | — | $40M |
| 2015 | — | -$40M | — | — | — | — | $51M |
| 2014 | — | $20M | — | — | — | — | $61M |
| 2013 | — | -$21M | — | — | -$40M | — | $65M |
| 2012 | — | -$29M | — | — | -$47M | — | $89M |
| 2011 | — | -$10M | — | — | -$29M | — | $88M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $52M | -$49M | 0.0% | -97.1% | -$50M | — | $54M |
| Dec '25 | $57M | -$141M | 0.0% | -70.5% | -$30M | — | $85M |
| Sep '25 | $56M | -$23M | 0.0% | -55.6% | -$32M | — | $70M |
| Jun '25 | $53M | -$27M | 0.0% | -73.2% | -$16M | — | $81M |
| Mar '25 | $50M | -$29M | 0.0% | -82.0% | -$34M | — | $112M |
| Dec '24 | $53M | -$5M | 0.0% | -19.3% | -$2M | — | $102M |
| Sep '24 | $48M | -$5M | 0.0% | -23.1% | -$15M | — | $100M |
| Jun '24 | $50M | -$5M | 0.0% | -20.1% | -$7M | — | $103M |
| Mar '24 | $47M | -$4M | 0.0% | -19.5% | $8M | — | $125M |
| Dec '23 | $45M | -$2M | 0.0% | -15.7% | -$4M | — | $136M |
| Sep '23 | $39M | $137000 | 0.0% | -15.4% | -$2M | — | $183M |
| Jun '23 | $46M | $2M | 0.0% | -6.2% | -$13M | — | $150M |
| Mar '23 | $62M | $3M | 0.0% | 3.2% | $32M | — | $354M |
| Dec '22 | $64M | $7M | 0.0% | 10.3% | $9M | — | $135M |
| Sep '22 | $65M | $3M | 0.0% | 6.0% | $13M | — | $49M |
| Jun '22 | $64M | $3M | 0.0% | 5.4% | $5M | — | $58M |
| Mar '22 | $60M | -$6M | 0.0% | -12.7% | $4M | — | $67M |
| Dec '21 | $68M | $7M | 0.0% | 12.7% | $26M | — | $52M |
| Sep '21 | $70M | $8M | 0.0% | 15.4% | $9M | — | $51M |
| Jun '21 | $68M | $10M | 0.0% | 18.2% | $19M | — | $57M |
How the market has priced VNDA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Vanda Pharmaceuticals Inc.'s revenue has declined 2.7% per year. These are computed facts, not advice.
As of FY2025, Vanda Pharmaceuticals Inc. reported — of total debt against $85M of cash.
In FY2025, gross margin was —, operating margin -70.0%, and net margin -102.0%.
As of Jun '26, Vanda Pharmaceuticals Inc. traded at a price-to-earnings ratio of about 123.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.